Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
Metagenomi’s $100 Million Series B Extension Financing
Rezo Therapeutics’ $78 Million Series A Financing
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
UPSIDE Foods’ $400 Million Series C Funding Round
Wilson Sonsini advised Temasek on the deal. UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, announced the close...
Affini-T Therapeutics’ $175 Million Financing
Latham & Watkins and Wilson Sonsini represented Affini-T Therapeutics, Inc. in the transaction. Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic...
Metagenomi’s $175 Million Series B Financing
Fenwick & West and Wilson Sonsini Goodrich & Rosati advised Metagenomi on the deal while Gunderson Dettmer represented PFM Health Sciences. Metagenomi, a genetic medicines company...
Metagenomi’s Collaboration with Moderna
Fenwick & West and Wilson Sonsini Goodrich & Rosati represented Metagenomi on the deal. Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation...
Regor Therapeutics’ $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on the deal. Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...